Comparative Pharmacology
Head-to-head clinical analysis: CHLOROMYXIN versus CUBICIN RF.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLOROMYXIN versus CUBICIN RF.
CHLOROMYXIN vs CUBICIN RF
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Chloromyxin is a combination product of chloramphenicol and polymyxin B. Chloramphenicol inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation. Polymyxin B disrupts bacterial cell membrane integrity by interacting with lipopolysaccharides in gram-negative bacteria.
Daptomycin is a cyclic lipopeptide antibiotic that binds to bacterial cell membranes, causing rapid depolarization and disruption of membrane potential, leading to cell death.
500 mg IV every 6 hours or 1 g IV every 12 hours; infusion over 30 minutes.
Adults: 6 mg/kg IV over 30-60 minutes every 24 hours. For deep-seated infections (e.g., endocarditis, osteomyelitis), consider 10 mg/kg IV every 24 hours.
None Documented
None Documented
CHLOROMYXIN is not a recognized drug. No data available.
Terminal elimination half-life: approximately 8-9 hours in patients with normal renal function; prolonged in renal impairment.
CHLOROMYXIN is not a recognized drug. No data available.
Renal excretion: approximately 80% of the dose as unchanged drug; biliary/fecal elimination: minor (<5%).
Category C
Category C
Antibiotic
Antibiotic